ethyl 6-(4-cyanophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate | 764659-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 6-(4-cyanophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
• 英文别名: 1-(4-methoxyphenyl)-6-(4-cyanophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester；6-(4-cyano-phenyl)-1-(4-methoxy-phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester；ethyl 6-(4-cyanophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate
• CAS: 764659-60-1
• 化学式: C₂₃H₂₀N₄O₄
• 分子量: 416.436
• InChiKey: JUVVBUBTHGVPKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  97.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 6-(4-cyanophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate 在 氯甲酸乙酯 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 5.0h， 生成 1-(4-methoxyphenyl)-6-(4-cyanophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element

  摘要：

  Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazoleitetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50 (FXa) value of 0.15 mu M and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.09.024
• 作为产物：
  描述：

  [(4-甲氧基苯基)肼基]氯乙酸乙酯 在 盐酸 、 三乙胺 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 ethyl 6-(4-cyanophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
  参考文献：
  名称：

  吡唑并[3,4-c]吡啶-7-酮类化合物及其应用

  摘要：

  本发明属于医药技术领域，涉及通式I所示的含4,5‑二氢‑1H‑吡唑并[3,4‑c]吡啶‑7‑酮衍生物及其药学上可接受的盐、水合物或前药，其中取代基A、R1和R2具有在说明书中给出的含义。本发明还涉及通式I的化合物及其药学上可接受的盐或前药的制备方法、含上述化合物的药用组合物以及上述化合物用作Xa因子抑制剂的用途，尤其在制备治疗和/或预防血栓栓塞性疾病的药物中的用途。

  公开号：

  CN104513239B

文献信息

• Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
  申请人：——

  公开号：US20040209863A1

  公开（公告）日：2004-10-21

  The present application describes sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds and derivatives thereof of Formula I: P 4 —P—M—M 4 I or pharmaceutically acceptable salt forms thereof, wherein M is a ring, P is an optional ring, and P 4 and M 4 are as defined below. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了含有磺酰胺基和四氢嘧啶基的化合物及其衍生物，其化学式为I：P4-P-M-M4I，或其药学上可接受的盐形式，其中M是环，P是可选环，P4和M4如下定义。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是Xa因子的抑制剂。
• [EN] SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS<br/>[FR] COMPOSES CONTENANT UN GROUPE SULFONYL-AMIDINO ET UN GROUPE TETRAHYDROPYRIMIDINO UTILISES COMME INHIBITEURS DE FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004083174A3

  公开（公告）日：2004-11-25
• US7122557B2
  申请人：——

  公开号：US7122557B2

  公开（公告）日：2006-10-17
• 吡唑并[3,4-c]吡啶-7-酮类化合物及其应用
  申请人：沈阳药科大学

  公开号：CN104513239B

  公开（公告）日：2017-08-22

  本发明属于医药技术领域，涉及通式I所示的含4,5‑二氢‑1H‑吡唑并[3,4‑c]吡啶‑7‑酮衍生物及其药学上可接受的盐、水合物或前药，其中取代基A、R1和R2具有在说明书中给出的含义。本发明还涉及通式I的化合物及其药学上可接受的盐或前药的制备方法、含上述化合物的药用组合物以及上述化合物用作Xa因子抑制剂的用途，尤其在制备治疗和/或预防血栓栓塞性疾病的药物中的用途。
• Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element
  作者：Yong Wang、Xiaoqing Sun、Di Yang、Zhuang Guo、Xuxu Fan、Minhua Nie、Feng Zhang、Yue Liu、Yue Li、Yulin Wang、Ping Gong、Yajing Liu

  DOI：10.1016/j.bmc.2016.09.024

  日期：2016.11

  Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazoleitetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50 (FXa) value of 0.15 mu M and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor. (C) 2016 Elsevier Ltd. All rights reserved.